Search

Amgen Inc

Suletud

SektorTervishoid

407.09 -1.38

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

399.53

Max

412.98

Põhinäitajad

By Trading Economics

Sissetulek

556M

2.4B

Müük

1.4B

10B

P/E

Sektori keskmine

25.03

47.946

Aktsiakasum

6.29

Dividenditootlus

2.43

Kasumimarginaal

23.622

Töötajad

31,500

EBITDA

-416M

3.4B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-2.37% downside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

2.43%

2.27%

Järgmine tulemuste avaldamine

3. nov 2026

Järgmine dividendimakse kuupäev

11. dets 2026

Järgmine aktsia dividendi kuupäev (ex-date)

20. nov 2026

Turustatistika

By TradingEconomics

Turukapital

13B

218B

Eelmine avamishind

408.47

Eelmine sulgemishind

407.09

Uudiste sentiment

By Acuity

51%

49%

248 / 340 Pingereas Healthcare

Amgen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. okt 2026, 23:01 UTC

Amgen Inc shares are trading modestly higher in after-market hours, remaining above their 20-day moving average amid rising oil prices and inflation concerns.

7. okt 2026, 23:11 UTC

Amgen Inc's shares declined slightly during after-market hours on Wednesday, following initial gains and positioning just below the regular session opening level.

6. okt 2026, 23:15 UTC

Amgen Inc is trading modestly lower in after-market hours following a slight recovery earlier in the session, remaining in the middle of its one-month trading range.

2. okt 2026, 20:07 UTC

Amgen Inc shares fell, continuing a downward trend with a cumulative drop since Thursday's close amid broader market declines.

1. okt 2026, 23:05 UTC

Amgen Inc. is trading higher in after-market hours, despite a notable drop from an early high and marking its fourth consecutive session of lower closes.

30. sept 2026, 23:40 UTC

Amgen Inc is trading modestly higher in after-market hours, supported by broader market gains and positive U.S. GDP and private sector job growth data.

29. sept 2026, 20:07 UTC

News

Scotiabank raised Amgen's price target to $500 from $450, contributing to the stock's gains amid positive trial results for dazodalibep in systemic Sjögren's disease.

28. sept 2026, 23:26 UTC

News

Amgen Inc's shares declined in after-market hours following the FDA's approval of Teva's Degevma, a biosimilar to Amgen's Xgeva, impacting its market position.

24. sept 2026, 19:56 UTC

News

Amgen Inc shares are higher following positive topline results from its Phase 3 OASIZ 301 trial for dazodalibep in treating systemic Sjögren's disease.

23. sept 2026, 23:41 UTC

Amgen Inc's shares are modestly higher in after-market trading, positioned near the midpoint of their one-month trading range.

22. sept 2026, 20:01 UTC

Social Media
News

Amgen shares advanced as the company reported positive topline results from its Phase 3 OASIZ 301 study for Sjögren's disease, achieving its primary endpoint.

21. sept 2026, 20:06 UTC

Amgen Inc is advancing today, continuing its upward trajectory since Friday's close, despite remaining below its 20-day moving average.

18. sept 2026, 20:06 UTC

Amgen Inc is trading higher on Friday, having advanced since Thursday's close, despite pulling back from an earlier session peak.

17. sept 2026, 19:46 UTC

Macro Event

Amgen Inc is trading modestly higher, despite earlier fluctuations and remaining below its 20-day moving average amid a decline in U.S. jobless claims.

16. sept 2026, 20:10 UTC

News

Amgen Inc has expanded its partnership with Veeva Systems, selecting Veeva Vault CRM to enhance global commercial execution, as shares trade slightly higher.

15. sept 2026, 23:01 UTC

Amgen Inc shares are higher in after-market trading, reflecting a recovery from earlier losses despite being below its 20-day moving average and one-month range.

14. sept 2026, 20:08 UTC

Social Media
News

Amgen Inc. shares rise after FDA approval for IMDELLTRA, reducing monitoring time for patients with extensive-stage small cell lung cancer. Positive sentiment noted on social media.

11. sept 2026, 20:08 UTC

Macro Event

Amgen Inc shares are lower today following a drop in the Michigan Consumer Sentiment index, raising concerns over inflation and household budgets.

10. sept 2026, 23:41 UTC

Amgen Inc. shares are higher in after-market trading, continuing a modest advance since Thursday's close, despite four consecutive lower daily closes.

8. sept 2026, 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

4. sept 2026, 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

3. sept 2026, 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2. sept 2026, 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

1. sept 2026, 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

31. aug 2026, 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

28. aug 2026, 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

27. aug 2026, 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

26. aug 2026, 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

25. aug 2026, 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

24. aug 2026, 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Amgen Inc Prognoos

Hinnasiht

By TipRanks

-2.37% langus

12 kuu keskmine prognoos

Keskmine 403.292 USD  -2.37%

Kõrge 500 USD

Madal 230 USD

Põhineb 27 Wall Streeti analüütiku instrumendi Amgen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

27 ratings

9

Osta

16

Hoia

2

Müü

Sentiment

By Acuity

248 / 340 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.